Foravirumab ELISA Kit

Foravirumab (CR4098), is currently under phase II clinical trial in the form of a cocktail with rafivirumab (CR57), a mAb derived from somatic cell hybridization targeting rabies virus glycoprotein antigenic site I.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.